Sign up to receive updates as information becomes available.
Accrufer is contraindicated in patients with a history of:
Increased Risk of Inflammatory Bowel Disease (IBD) Flare
Avoid use of Accrufer in patients with an active IBD flare, as there is potential risk of increased inflammation in the gastrointestinal tract.
Excessive therapy with iron products can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Do not administer Accrufer to patients with evidence of iron overload or patients receiving intravenous iron. Assess iron parameters prior to initiating Accrufer and monitor iron parameters while on therapy.
Risk of Overdosage in Children Due to Accidental Ingestion
Accidental overdose of iron products is a leading cause of fatal poisoning in children under age 6. Keep out of reach of children.
Most common adverse reactions (≥2%) reported with Accrufer were flatulence (4.6%), diarrhea (4%), constipation (4%), discolored feces (4%) and abdominal pain (2.9%).